Yield10 Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>YB</div>
YTEN -- USA Stock  

USD 14.44  0.09  0.63%

The upcoming quarterly report is expected on the 18th of March 2021. The stock is still going through an active upward rally. Yield10 Bioscience Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 49.68 Million. Tangible Asset Value is expected to rise to about 12.7 M this year, although the value of Net Income Per Employee will most likely fall to (470.5 K). Although many aggressive traders are getting into basic materials space, Yield10 Bioscience may or may not be your first choice.
Published over a month ago
View all stories for Yield10 Bioscience | View All Stories
How much will Yield10 Bioscience owe in February?
The company currently holds 3.73 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. Yield10 Bioscience has a current ratio of 8.21, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Yield10 Bioscience financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Yield10 Bioscience, including all of Yield10 Bioscience's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Yield10 Bioscience assets, the company is considered highly leveraged. Understanding the composition and structure of overall Yield10 Bioscience debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Yield10 Total Debt

Yield10 Bioscience liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Yield10 Bioscience has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Yield10 Bioscience balance sheet include debt obligations and money owed to different Yield10 Bioscience vendors, workers, and loan providers. Below is the chart of Yield10 main long-term debt accounts currently reported on its balance sheet.
You can use Yield10 Bioscience financial leverage analysis tool to get a better grip on understanding its financial position

How important is Yield10 Bioscience's Liquidity

Yield10 Bioscience financial leverage refers to using borrowed capital as a funding source to finance Yield10 Bioscience ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Yield10 Bioscience financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Yield10 Bioscience's total debt and its cash.

Yield10 Bioscience exotic insider transaction detected

Legal trades by Yield10 Bioscience insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Yield10 insider trading alert for general transaction of common stock by Kristi Snell, VP Research & CSO, on 16th of February 2021. This event was filed by Yield10 Bioscience Inc with SEC on 2021-02-16. Statement of changes in beneficial ownership - SEC Form 4. Kristi Snell currently serves as chief science officer, vice president - research of Yield10 Bioscience [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Yield10 Bioscience valued adequately by the market?

The latest price rise of Yield10 Bioscience may raise some interest from institutional investors as it is trading at a share price of 7.75 on very low momentum in trading volume. The company directors and management may have good odds in positioning the company resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.4. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Yield10 Bioscience partners.

Liabilities Breakdown

4.7 M
Current Liabilities
1.9 M
Long-Term Liabilities
Total Liabilities5.17 Million
Current Liabilities4.7 Million
Long-Term Liabilities1.91 Million

Another 3 percent rise for Yield10 Bioscience

Potential upside is down to 5.52. It may entail a possible volatility slide. As of the 15th of January 2021, Yield10 Bioscience maintains the Market Risk Adjusted Performance of 0.233, mean deviation of 2.47, and Downside Deviation of 3.22. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Yield10 Bioscience, as well as the relationship between them. Specifically, you can use this information to find out if the company will indeed mirror its model of past data patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Yield10 Bioscience, which can be compared to its rivals. Please check out Yield10 Bioscience downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Yield10 Bioscience is priced fairly, providing market reflects its latest price of 7.75 per share. Given that Yield10 Bioscience has jensen alpha of 0.1128, we strongly advise you to confirm Yield10 Bioscience's prevalent market performance to make sure the company can sustain itself at a future point.

Whereas many other companies under the agricultural inputs industry are still a bit expensive, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Yield10 as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Yield10 Bioscience.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Yield10 Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com